Stocks Health care VKTX
NASDAQ · Health careViking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. brought in $0 of revenue over the twelve months to June 30, 2026. It posted a net loss of $534.8M. At June 30, 2026 it held $125.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 29, 2026.
What Viking Therapeutics, Inc. does
Viking Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VKTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$359.6M | -$3.19 | n/a |
| 2024 | $0 | -$110M | -$1.01 | n/a |
| 2023 | $0 | -$85.9M | -$0.91 | n/a |
| 2022 | $0 | -$68.9M | -$0.90 | n/a |
| 2021 | $0 | -$55M | -$0.71 | n/a |
| 2020 | $0 | -$39.5M | -$0.54 | n/a |
Latest SEC filings
What Viking Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026
- September 25, 2026
- September 24, 2026
- September 24, 2026Form 305B2 filing 305B2
- September 23, 2026
- September 23, 2026
- September 22, 2026Other event 8-K
- July 30, 2026
- July 29, 2026Quarterly report 10-Q · period to June 30, 2026
- July 29, 2026
Questions about VKTX
What does Viking Therapeutics, Inc. do?
Viking Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VKTX.
Is Viking Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $534.8M.
How much revenue does Viking Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Viking Therapeutics, Inc. reported revenue of $0.
When did Viking Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 29, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the securities offering prospectus from September 25, 2026.
Similar companies
Follow VKTX
Get an email when Viking Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow VKTX: get an email when it filesWhere the numbers come from
Financial figures are the values Viking Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.